The most severe cases can cause skin atrophy, ulceration and gangrene.

Skin may shrink and waste away (skin atrophy).

Compared to other topical corticosteroids, like betamethasone, repeated prednicarbate use does not cause skin atrophy as quickly.

Chronic widespread use of potent topical corticosteroids may produce local skin atrophy and systemic adverse effects.

A common potential adverse effect is skin atrophy (thinning of the skin).

The skin atrophy was referred to as vermiculate atrophoderma.

Even low-potency topical steroids can cause slight skin atrophy that often reverses upon discontinuation of the drugs.

Atrophoderma refers to conditions involving skin atrophy.

The disease is characterized by early-onset dementia, ataxia, muscle wasting, skin atrophy, and eye abnormalities.

In addition, in contrast with topical steroids, pimecrolimus does not produce skin atrophy.